Found: 57
Select item for more details and to access through your institution.
BAD partly reverses paclitaxel resistance in human ovarian cancer cells.
- Published in:
- Oncogene, 1998, v. 17, n. 19, p. 2419, doi. 10.1038/sj.onc.1202180
- By:
- Publication type:
- Article
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.
- Published in:
- Journal of Bone & Mineral Research, 2016, v. 31, n. 6, p. 1225, doi. 10.1002/jbmr.2789
- By:
- Publication type:
- Article
Myeloma Immune and Antibody Targets.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, p. S18
- By:
- Publication type:
- Article
CD52 Is Expressed on Human Mast Cells and Is a Potential Therapeutic Target in Waldenström's Macroglobulinemia and Mast Cell Disorders.
- Published in:
- Clinical Lymphoma & Myeloma, 2006, v. 6, n. 6, p. 478
- By:
- Publication type:
- Article
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.
- Published in:
- Nature Communications, 2016, v. 7, n. 1, p. 10258, doi. 10.1038/ncomms10258
- By:
- Publication type:
- Article
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.01821
- By:
- Publication type:
- Article
Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.01822
- By:
- Publication type:
- Article
Immunotherapeutic and Targeted Approaches in Multiple Myeloma.
- Published in:
- ImmunoTargets & Therapy, 2020, v. 9, p. 201, doi. 10.2147/ITT.S240886
- By:
- Publication type:
- Article
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
- Published in:
- Oncogene, 2004, v. 23, n. 54, p. 8766, doi. 10.1038/sj.onc.1208118
- By:
- Publication type:
- Article
Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Preclinical evaluation of CD8+ Anti-BCMA mRNA CAR T-Cells for control of multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e169, doi. 10.1016/j.clml.2019.09.283
- By:
- Publication type:
- Article
Mechanisms, biologic sequelae and clinical benefits of bortezomib-induced immunogenic cell death in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e162, doi. 10.1016/j.clml.2019.09.270
- By:
- Publication type:
- Article
MEDI2228, a novel BCMA pyrrolobenzodiazepine antibody drug conjugate, overcomes drug resistance and synergizes with bortezomib and DNA damage response inhibitors in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e154, doi. 10.1016/j.clml.2019.09.257
- By:
- Publication type:
- Article
KDM5A reinforces MYC transcriptional program and promotes myeloma cell growth.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e132, doi. 10.1016/j.clml.2019.09.220
- By:
- Publication type:
- Article
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e107, doi. 10.1016/j.clml.2019.09.176
- By:
- Publication type:
- Article
Roundabout 1 (ROBO1) Mediates Multiple Myeloma Survival and Interaction with the Bone Marrow Microenvironment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e103, doi. 10.1016/j.clml.2019.09.170
- By:
- Publication type:
- Article
AMG 701, a half-life extended anti-BCMA BiTE®, potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the immunosuppressive bone marrow microenvironment.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e54, doi. 10.1016/j.clml.2019.09.082
- By:
- Publication type:
- Article
APOBEC3B is induced by activation of DNA damage pathway and regulates the survival and treatment response in human multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e51, doi. 10.1016/j.clml.2019.09.078
- By:
- Publication type:
- Article
Impact of Chromosome 6q Deletions in Multiple Myeloma and Waldenström's Macroglobulinemia by Next Generation RNA Sequencing.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e39, doi. 10.1016/j.clml.2019.09.059
- By:
- Publication type:
- Article
Checkpoint expression on immune cells in the patients with multiple myeloma or pre-malignant diseases: Therapeutic Implication for Combination Immu.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e26, doi. 10.1016/j.clml.2019.09.039
- By:
- Publication type:
- Article
PHF19 Promotes Drug Resistance via Increased EZH2 Phosphorylation in Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e21, doi. 10.1016/j.clml.2019.09.031
- By:
- Publication type:
- Article
Cooperative impact of Utx loss and Braf V600E mutation induces myeloma in mice.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e20, doi. 10.1016/j.clml.2019.09.030
- By:
- Publication type:
- Article
Genome wide chromatin accessibility profiling identifies chromatin signatures and novel transcription factor dependencies in multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e8, doi. 10.1016/j.clml.2019.09.011
- By:
- Publication type:
- Article
Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e5, doi. 10.1016/j.clml.2019.09.007
- By:
- Publication type:
- Article
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00787-w
- By:
- Publication type:
- Article
γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 8, p. 1, doi. 10.1038/s41408-022-00716-3
- By:
- Publication type:
- Article
Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 4, p. 1, doi. 10.1038/s41408-022-00635-3
- By:
- Publication type:
- Article
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.
- Published in:
- British Journal of Haematology, 2012, v. 157, n. 6, p. 718, doi. 10.1111/j.1365-2141.2012.09120.x
- By:
- Publication type:
- Article
A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma.
- Published in:
- British Journal of Haematology, 2012, v. 157, n. 6, p. 687, doi. 10.1111/j.1365-2141.2012.09111.x
- By:
- Publication type:
- Article
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
- Published in:
- British Journal of Haematology, 2011, v. 155, n. 4, p. 438, doi. 10.1111/j.1365-2141.2011.08864.x
- By:
- Publication type:
- Article
Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.
- Published in:
- British Journal of Haematology, 2011, v. 155, n. 3, p. 349, doi. 10.1111/j.1365-2141.2011.08850.x
- By:
- Publication type:
- Article
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
- Published in:
- British Journal of Haematology, 2007, v. 138, n. 6, p. 783, doi. 10.1111/j.1365-2141.2007.06714.x
- By:
- Publication type:
- Article
research paper Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
- Published in:
- British Journal of Haematology, 2004, v. 125, n. 3, p. 343, doi. 10.1111/j.1365-2141.2004.04929.x
- By:
- Publication type:
- Article
Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival.
- Published in:
- British Journal of Haematology, 2003, v. 123, n. 5, p. 869, doi. 10.1046/j.1365-2141.2003.04686.x
- By:
- Publication type:
- Article
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.
- Published in:
- British Journal of Haematology, 2003, v. 121, n. 4, p. 592, doi. 10.1046/j.1365-2141.2003.04322.x
- By:
- Publication type:
- Article
Cell of the month: Image competition.
- Published in:
- Nature Reviews Molecular Cell Biology, 2003, v. 4, n. 9, p. 677, doi. 10.1038/nrm1217
- By:
- Publication type:
- Article
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-21177-5
- By:
- Publication type:
- Article
MUC1-C is a target in lenalidomide resistant multiple myeloma.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 6, p. 914, doi. 10.1111/bjh.14801
- By:
- Publication type:
- Article
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 5, p. 735, doi. 10.1111/bjh.13897
- By:
- Publication type:
- Article
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-30694-w
- By:
- Publication type:
- Article
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Simple and reliable way in sternum wound coverage-Tripedicle pectoralis major musculocutaneous flap.
- Published in:
- Microsurgery, 2008, v. 28, n. 6, p. 441, doi. 10.1002/micr.20534
- By:
- Publication type:
- Article
Penile replantation, complication management, and technique refinement.
- Published in:
- Microsurgery, 2008, v. 28, n. 3, p. 153, doi. 10.1002/micr.20470
- By:
- Publication type:
- Article
Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma.
- Published in:
- Communications Biology, 2021, v. 4, n. 1, p. 1, doi. 10.1038/s42003-021-02125-x
- By:
- Publication type:
- Article
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-45561-z
- By:
- Publication type:
- Article
OPINION: Neurons from stem cells: preventing an identity crisis.
- Published in:
- Nature Reviews Neuroscience, 2001, v. 2, n. 11, p. 831, doi. 10.1038/35097581
- By:
- Publication type:
- Article
Genomic landscape and chronological reconstruction of driver events in multiple myeloma.
- Published in:
- Nature Communications, 2019, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41467-019-11680-1
- By:
- Publication type:
- Article
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
- Published in:
- Clinical Pharmacology, 2021, v. 13, p. 169, doi. 10.2147/CPAA.S288840
- By:
- Publication type:
- Article
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
- Published in:
- Cancers, 2021, v. 13, n. 23, p. 6136, doi. 10.3390/cancers13236136
- By:
- Publication type:
- Article